In conclusion, our findings show that the benefits of anti-PD1 agents are greater in ICC than in other advanced BTCs, providing the possibility of immunotherapy as an option based on the anatomical locations of the BTCs. This evidence concerns the gene PDCD1 and intrahepatic cholangiocarcinoma.